Citigroup Inc Chemo Centryx, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	SELL	$22.17 - $51.8 $404,757 - $945,712	-18,257 Reduced 11.45%	141,170 $7.29 Million
Q2 2022 Aug 10, 2022	BUY	$15.36 - $27.51 $1.8 Million - $3.22 Million	117,029 Added 276.02%	159,427 $3.95 Million
Q1 2022 May 12, 2022	SELL	$22.22 - $39.12 $2.02 Million - $3.55 Million	-90,869 Reduced 68.19%	42,398 $1.06 Million
Q4 2021 Feb 10, 2022	SELL	$18.38 - $40.5 $1.29 Million - $2.84 Million	-70,233 Reduced 34.51%	133,267 $4.85 Million
Q3 2021 Nov 10, 2021	BUY	$13.18 - $19.83 $2.68 Million - $4.04 Million	203,500 New	203,500 $3.48 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.